Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our findings show that CCL2 levels are associated with dyslipidemia, which suggests a role of this cytokine in the pathogenesis of cardiovascular disease in HD patients.
|
31557637 |
2020 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
To determine the association between MCP-1, FGF-21 and subclinical atherosclerosis [i.e., carotid intima-media thickness (cIMT)] in women without clinical evidence of CVD.
|
31152776 |
2019 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Additionally, CX<sub>3</sub>CL1/CX<sub>3</sub>CR1 or CCL2/CCR2 axes are potential candidates for therapeutic intervention in cardiovascular disorders in metabolic syndrome patients, as their blockade impairs the augmented arterial platelet-Mon1 monocyte aggregate adhesiveness, which is a key event in atherogenesis.
|
31109070 |
2019 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
A novel electrochemical immunosensor was proposed for the detection of monocyte chemoattractant protein-1 (MCP-1), a biomarker of cardiovascular disease.
|
30826652 |
2019 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor 21 (FGF-21) and monocyte chemoattractant protein 1 (MCP-1) are associated with cardiovascular disease and systemic inflammation.
|
31429530 |
2019 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
CCL2 played important roles in regulating platelet function and arterial thrombosis through the PKCα-P38MAPK-HSP27 pathway, which might provide theoretical basis for searching new antiplatelet drugs and the treatment for cardiovascular diseases.
|
29864522 |
2018 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Although the serum MCP-1 concentration is higher in patients with than without cardiovascular disease, the precise correlations between the serum MCP-1 concentration and factors associated with smoking and atherosclerosis are unknown.
|
29098933 |
2018 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
This review presents the importance of these monocyte subsets in cardiovascular diseases (CVDs), and sheds light on new strategies for the blocking of the MCP-1/CCR2 axis as a therapeutic goal for treating vascular disorders.
|
28566450 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Higher concentrations of urine α1m, MCP-1, and PINP may identify KTRs at higher risk for CVD events and death.
|
28371433 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Reduction in ICAM-1 and MCP-1 in human endothelium is an important extent of the use of this drug for treatment of cardiovascular diseases, and NO has an important role in this process.
|
28371087 |
2017 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Obesity is associated with elevated monocyte chemoattractant protein-1 (MCP-1), a proinflammatory chemokine related to diabetes and cardiovascular disease.
|
25994074 |
2015 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Both lower and higher MCP-1 levels are associated with an increased risk of all-cause and CVD mortality among CAD patients.
|
25786118 |
2015 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
These results demonstrate that MCPIP may be an important regulator of inflammatory angiogenesis and provide novel mechanistic insights into the link between MCP-1 and cardiovascular diseases.
|
24008336 |
2013 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, anti-inflammatory gene therapy targeting MCP-1/CCR2 signal, with a novel NP-mediated gene delivery system, is a potent therapeutic strategy for the treatment of cardiovascular diseases.
|
22023473 |
2011 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) is a potent chemokine and plays an important role in cardiovascular diseases.
|
19781803 |
2009 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
LHGDN |
There was no statistically significant difference in the distribution of MCP-1 genotypes between ESRD patients without CVD and healthy controls.
|
19014891 |
2008 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We measured CRP (by immunonephelometry) and monocyte expression of TF and MCP-1 (by real-time PCR) in 80 untreated hypertensive patients without clinical cardiovascular disease (CVD) or additional risk factors for CVD compared with 41 controls.
|
18339698 |
2008 |
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
There was no statistically significant difference in the distribution of MCP-1 genotypes between ESRD patients without CVD and healthy controls.
|
19014891 |
2008 |
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Thus the augmented MCP-1 expression by ANG II in preadipocytes may provide a new link between obesity and cardiovascular disease.
|
16705055 |
2006 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
LHGDN |
This interaction may reflect the new role of MCP-1 as an arteriogenic factor in HD patients with CVD.
|
15627719 |
2005 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
CTD_human |
Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: interactions with genotype and equol production.
|
16332659 |
2005 |
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Multivariate analyses on 64 study subjects of varying arsenic exposure levels showed that the association of CCL2/MCP1 plasma protein level with blood arsenic remained significant after adjustment for other risk factors of cardiovascular diseases.
|
12928151 |
2003 |